- Home
- WD vs RIGL Comparison
WD vs RIGL Comparison
Compare WD & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WD | RIGL |
|---|---|---|
| Founded | 1937 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 911.8M |
| IPO Year | 2010 | 2000 |
Fundamental Metrics
Financial Performance| Metric | WD | RIGL |
|---|---|---|
| Price | $34.06 | $48.18 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | $48.33 | ★ $63.00 |
| AVG Volume (30 Days) | ★ 527.5K | 190.3K |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | ★ 7.84% | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | 0.55 | ★ 1.32 |
| Revenue | ★ $1,234,306,000.00 | $294,282,000.00 |
| Revenue This Year | $9.25 | $3.89 |
| Revenue Next Year | $9.48 | $21.95 |
| P/E Ratio | $63.17 | ★ $37.08 |
| Revenue Growth | 8.99 | ★ 64.15 |
| 52 Week Low | $31.40 | $24.84 |
| 52 Week High | $86.32 | $52.24 |
Technical Indicators
Market Signals| Indicator | WD | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 46.39 | 53.51 |
| Support Level | $31.40 | $44.50 |
| Resistance Level | $52.37 | $50.19 |
| Average True Range (ATR) | 1.55 | 1.76 |
| MACD | 0.41 | -0.01 |
| Stochastic Oscillator | 66.20 | 55.99 |
Price Performance
Historical ComparisonAbout WD Walker & Dunlop Inc
Walker & Dunlop Inc is a United States-based commercial real estate finance company. It is principally engaged in originating, selling, and servicing a number of multifamily and other commercial real estate financing products that are sold under the programs of Freddie Mac, Fannie Mae, Ginnie Mae, and the Federal Housing Administration. The company is managed based on three reportable segments: Capital Markets (CM), Servicing & Asset Management (SAM), and Corporate. The company generates a majority of its total revenue from gains from mortgage banking activities and servicing fees. It conducts business solely in the United States.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.